HOOKIPA PharmaHOOK 49 Market Cap is $14.23 Mil as of Jun. 25, 2026. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,431 Biotechnology companies, HOOKIPA Pharma ranks worse than 80.78% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). HOOKIPA Pharma's share price for the quarter that ended in Jun. 2025 was $1.255. HOOKIPA Pharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2025 was 12.20 Mil. Therefore, HOOKIPA Pharma's market cap for the quarter that ended in Jun. 2025 was $15.31 Mil.
HOOKIPA Pharma's quarterly market cap
declined
from Dec. 2024 ($24.23 Mil) to Mar. 2025 ($13.04 Mil) but then
increased
from Mar. 2025 ($13.04 Mil) to Jun. 2025 ($15.31 Mil).
HOOKIPA Pharma's annual market cap
increased
from Dec. 2022 ($61.81 Mil) to Dec. 2023 ($97.65 Mil) but then
declined
from Dec. 2023 ($97.65 Mil) to Dec. 2024 ($24.23 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. HOOKIPA Pharma's Enterprise Value for Today is $-19.45 Mil.
HOOKIPA Pharma (OTCPK:HOOK) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
HOOKIPA Pharma Market Cap Related Terms
HOOKIPA Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HOOKIPA Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
HOOKIPA Pharma's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a Market Cap of $14.23 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #1156 out of 1431 companies in the Biotechnology industry, placing it in the top 80.8%.
Is HOOKIPA Pharma's Market Cap too high?
HOOKIPA Pharma's current Market Cap is $14.23 Mil. The Biotechnology industry median Market Cap is 117.63. HOOKIPA Pharma's value of $14.23 Mil is 87.9% below this industry median. Based on the distribution chart, HOOKIPA Pharma ranks #1156 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Market Cap compare to LNAI and ZEOX?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #1156 out of 1431 companies for Market Cap. This places HOOKIPA Pharma in the lower half of its industry. The industry median Market Cap is 117.63. HOOKIPA Pharma's value of $14.23 Mil is 87.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOOKIPA Pharma's current Market Cap of $14.23 Mil is 87.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current Market Cap is $14.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current Market Cap is $14.23 Mil and 87.9% below the Biotechnology industry median of 117.63. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Market Cap is $14.23 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
Market Cap: $14.23 Mil
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
Industry Position: 87.9% below the Biotechnology median (#1156 of 1431)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score
Get the complete analysis for HOOK
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
